EUCTR2021-005771-39-HU招募中1 期
A Phase 2, randomised, double-blind, placebo-controlled, dose escalation study to investigate the effects of IRL201805 in participants with moderately to severely active rheumatoid arthritis - RVLO 221-02 IRL201805 in rheumatoid arthritis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 92
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •A participant must meet the following criteria to be eligible for inclusion in the study:
- •Demographic and Laboratory Assessments:
- •1.Participants are men or women ages = 18 and = 75 years.
- •2.Participant must have laboratory values meeting the criteria listed below within the screening period prior to the first dose of study drug. Outofrange laboratory parameters may be rechecked one time, after consultation with the sponsor or its designee, before the participant is considered a screen failure.
- •a.Serum alanine transaminase (ALT) < 2 × upper limit of normal (ULN)
- •b.Total white blood cell (WBC) count > 3000/µL
- •c.Absolute neutrophil count (ANC) > 1500/µL
- •d.Platelet count > 100,000/µL
- •e.Absolute lymphocyte count > 800/µL
- •f.Hemoglobin > 10 g/dL
- •3.Participant must have a negative test result for hepatitis A virus immunoglobulin M (HAVIgM), hepatitis B surface antigen (HBsAg), HBcAb (participants who have been vaccinated against hepatitis B [HB] and are HBsAb positive may be enrolled), hepatitis C virus (HCV) antibody (if hepatitis C RNA level is undetectable at Screening, the participant can participate in this study), and human immunodeficiency virus (HIV) Ab at Screening.
- •4.Participant must have a negative tuberculosis (TB) test: QuantiFERON TB-Gold In-Tube test (or equivalent if compliant with local TB guidelines) or purified protein derivative (PPD). Participants who have previously received an adequate course of therapy as per local standard of care for latent TB do not require TB test.
- •5.Participant is able and willing to provide written informed consent and comply with the requirements of the study protocol.
- •Diagnosis and Disease Activity:
- •6.Participant has a clinical diagnosis of RA for > 3 months based on the 1987 ACR classification criteria or 2010 ACR/European League against Rheumatism (EULAR) criteria.
- •7.Participant has moderately to severely active RA defined as: = 6 swollen joints (from a SJC66) and = 6 tender joints (from a TJC68) at both Screening and Baseline/Day 1.
- •8.Participant has a high-sensitivity C-reactive protein (hsCRP) = 3 mg/L at Screening.
- •9.Participant has an incomplete response to MTX. Participants must have been on oral or parenteral MTX therapy = 3 months and on a stable prescription of 15 to 25 mg/week (or = 10 mg/week in participants intolerant of methotrexate at doses = 15 mg/week) for = 4 weeks prior to the first dose of study drug. Participant must be expected to be able to continue on a stable dose of MTX for the duration of study participation. Dose adjustments are only permitted for the management of toxicity.
- •10.Prior treatment with additional conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) is allowed; however, the participant must be on MTX only at Baseline/Day 1 and an appropriate washout needs to be satisfied, as specified in the protocol (Section 9.2) to be eligible for the study.
- •11.Participants must have discontinued all biologic DMARD (bDMARD) and targeted synthetic DMARD (tsDMARD) therapy prior to the first dose of study drug. The washout period of these agents prior to the first dose of study drug is specified below or should at least 5 times the mean terminal elimination half-life of a drug:
- •a.= 4 weeks for etanercept, adalimumab, infliximab, certolizumab, golimumab, tocilizumab, and abatacept
- •b.prior rituximab treatment is not allowed
- •c.= 4 weeks for any tsDMARD (including but not limited to upadacitinib, tofacitinib, barici
排除标准
- •A participant who meets any of the following criteria will be ineligible to participate in this study:
- •Participant History
- •1.Participant has a history of persistent chronic or active infection(s) requiring hospitalization or treatment with parenteral anti-infectives within 30 days, or oral anti-infectives within 14 days prior to the first dose of study drug administration.
- •2.Participant has a history or evidence of active TB.
- •3.Participant has a history of malignancy within 5 years prior to Screening, except completely treated in situ carcinoma of the cervix and completely treated and resolved nonmetastatic squamous or basal cell carcinoma of the skin.
- •4.Participant has a history of clinically significant medical conditions or any other reason (eg, clinically significant drug or alcohol abuse) that the investigator determines would interfere with the participant's participation in this study or would make the participant an unsuitable candidate to receive study drug.
- •5.Participant has known hypersensitivity to IRL201805 or its excipients (ie, penicillin or aminoglycosides).
- •6.Participant is currently enrolled in another clinical study and/or has previously been enrolled in the current study.
- •Diagnosis and Disease Activity:
- •7.Participant has a history of being exposed to > 1 biologic (bDMARD) or targeted synthetic (tsDMARD) therapy for RA. Participants with exposure to 1 bDMARD and 1 tsDMARD are not eligible.
- •Concomitant Medications:
- •8.Participant is taking systemic glucocorticoids (GCs) > 7.5 mg/day prednisone equivalent. Stable dose of GC (= 7.5 mg/day prednisone equivalent) started at least 4 weeks prior to the Baseline/Day 1 visit is permitted.
- •9.Participant has been treated with an investigational drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug.
- •10.Participant has been treated with intra-articular, intramuscular, IV, trigger point or tender point, intrabursa, or intratendon sheet corticosteroids in the preceding 4 weeks prior to the first dose of the study drug.
- •11.Participant has received a live vaccine within 4 weeks prior to the first dose of study drug or expects to need a live vaccination during study participation.
- •Contraception:
- •12.Participant is a female who has a positive pregnancy test at Screening or Baseline/Day 1.
- •13.Participant is a female who is breastfeeding or considering becoming pregnant during the study.
研究者
相似试验
招募中
2 期
A Phase 2, randomised, double-blind, placebo-controlled, 2-way crossover study to evaluate the efficacy, safety, and tolerability of NMD670 in ambulatory adults with Type 3 spinal muscular atrophy5q spinal muscular atrophyAutosomal recessive proximal spinal muscular atrophy10029317NL-OMON56350MD Pharma5
招募中
1 期
Safety and efficacy of NMD670 in ambulatory adult patients with Type 3 spinal muscular atrophy (SYNAPSE-SMA)Type 3 spinal muscular atrophyMedDRA version: 20.0Level: LLTClassification code 10079415Term: Spinal muscular atrophy type IIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2022-002301-24-DKMD Pharma A/S54
进行中（未招募）
1 期
A clinical trial to investigate IRL201805 in patients with rheumatoid arthritisMedDRA version: 23.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2021-005771-39-CZRevolo Biotherapeutics Ltd92
招募中
1 期
A study to evaluate the efficacy, safety, and tolerability of oral NMD670 compared with placebo in ambulatory adults with spinal muscular atrophyType 3 spinal muscular atrophyMedDRA version: 20.0Level: LLTClassification code 10079415Term: Spinal muscular atrophy type IIISystem Organ Class: 100000004850EUCTR2022-002301-24-ESMD Pharma A/S54
招募中
1 期
Safety and efficacy of NMD670 in ambulatory adult patients with Type 3 spinal muscular atrophy (SYNAPSE-SMA)Type 3 spinal muscular atrophyMedDRA version: 20.0Level: LLTClassification code 10079415Term: Spinal muscular atrophy type IIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2022-002301-24-DEMD Pharma A/S54